Filtered By:
Drug: Actos
Education: Study

This page shows you your search results in order of relevance. This is page number 4.

Order by Relevance | Date

Total 72 results found since Jan 2013.

Risk factors associated with abnormal cognition in Japanese outpatients with diabetes, hypertension or dyslipidemia
Conclusions Because of the higher prevalence of abnormal cognition in aged outpatients with diabetes found in primary care practice and significant associations with serum albumin, uric acid, renal function, retinopathy and antidiabetic drugs, there is a need for early diagnosis and strategies against dementia.
Source: Diabetology International - November 9, 2014 Category: Endocrinology Source Type: research

Peroxisome Proliferator-Activated Receptor- γ in Thyroid Autoimmunity.
Authors: Ferrari SM, Fallahi P, Vita R, Antonelli A, Benvenga S Abstract Peroxisome proliferator-activated receptor- (PPAR-) γ expression has been shown in thyroid tissue from patients with thyroiditis or Graves' disease and furthermore in the orbital tissue of patients with Graves' ophthalmopathy (GO), such as in extraocular muscle cells. An increasing body of evidence shows the importance of the (C-X-C motif) receptor 3 (CXCR3) and cognate chemokines (C-X-C motif) ligand (CXCL)9, CXCL10, and CXCL11, in the T helper 1 immune response and in inflammatory diseases such as thyroid autoimmune disorders. PPAR-γ agoni...
Source: PPAR Research - February 28, 2015 Category: Genetics & Stem Cells Tags: PPAR Res Source Type: research

Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial
Publication date: Available online 23 June 2015 Source:The Lancet Neurology Background A systematic assessment of potential disease-modifying compounds for Parkinson's disease concluded that pioglitazone could hold promise for the treatment of patients with this disease. We assessed the effect of pioglitazone on the progression of Parkinson's disease in a multicentre, double-blind, placebo-controlled, futility clinical trial. Methods Participants with the diagnosis of early Parkinson's disease on a stable regimen of 1 mg/day rasagiline or 10 mg/day selegiline were randomly assigned (1:1:1) to 15 mg/day pioglitazone, 45 mg...
Source: The Lancet Neurology - June 24, 2015 Category: Neurology Source Type: research

Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis
Publication date: Available online 11 August 2015 Source:The Lancet Diabetes & Endocrinology Author(s): Miles Fisher, Mark C Petrie, Philip D Ambery, Jill Donaldson, John J V McMurray, June Ye Background Albiglutide is a glucagon-like peptide-1 receptor agonist, a new class of drugs used to treat type 2 diabetes. We did a prospective meta-analysis of the cardiovascular safety of albiglutide as stipulated by the US Food and Drug Administration recommendations for the assessment of new treatments for diabetes. Methods We did a meta-analysis of eight phase 3 trials and one phase 2b trial in which patients wer...
Source: The Lancet Diabetes and Endocrinology - August 12, 2015 Category: Endocrinology Source Type: research

Diabetes Drug May Help Prevent Second Stroke: Study
Actos reduced risk by 24 percent in people with insulin resistance, research showed
Source: U.S. News - Health - February 17, 2016 Category: Consumer Health News Source Type: news

Pioglitazone for Secondary Prevention in Vascular Disease? (FREE)
By Joe Elia Edited by Jaye Elizabeth Hefner, MD Pioglitazone, which lowers insulin resistance, may help in the secondary prevention of vascular events, suggests a study presented at the International Stroke Conference and published in the New England …
Source: Physician's First Watch current issue - February 18, 2016 Category: Primary Care Source Type: news

Diabetes Drug May Help Prevent Second Stroke: Study
Actos reduced risk by 24 percent in people with insulin resistance, research showed
Source: WebMD Health - February 17, 2016 Category: Consumer Health News Source Type: news

Antidiabetic agents and cardiovascular outcomes in patients with heart diseases.
This article reviews evidence of benefits and risk of antidiabetic agents in cardiovascular (CV) outcomes, with a focus on medications approved by the FDA since 2008. Peer-reviewed articles were identified from MEDLINE and Current Content database (both 1966 to October 1, 2016) using the search terms insulin, metformin, rosiglitazone, pioglitazone, glyburide, glipizide, glimepiride, acarbose, miglitol, albiglutide, exenatide, liraglutide, lixisenatide, dulaglutide, pramlintide, meglitinide, alogliptin, linagliptin, saxagliptin, sitagliptin, canagliflozin, dapagliflozin, empagliflozin, colesevalam, bromocriptine, mortality,...
Source: Current Medical Research and Opinion - January 19, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research

Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?
Hyperglycemia is the major risk factor for microvascular complications in patients with type 2 diabetes (T2D). However, cardiovascular disease (CVD) is the principal cause of death, and lowering HbA1c has only a modest effect on reducing CVD risk and mortality. The recently published LEADER and SUSTAIN-6 trials demonstrate that, in T2D patients with high CVD risk, the glucagon-like peptide 1 receptor agonists liraglutide and semaglutide reduce the primary major adverse cardiac events (MACE) end point (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) by 13% and 24%, respectively. The EMPA-REG OUTCOME, ...
Source: Diabetes Care - June 21, 2017 Category: Endocrinology Authors: Abdul-Ghani, M.; DeFronzo, R. A.; Del Prato, S.; Chilton, R.; Singh, R.; Ryder, R. E. J. Tags: Epidemiology-Diabetes Complications Perspectives in Care Source Type: research

Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial
This study is registered with ClinicalTrials.gov, number NCT00700856. Findings Between Sept 18, 2008, and Jan 15, 2014, 3028 patients were randomly assigned and included in the analyses. 1535 were assigned to pioglitazone and 1493 to sulfonylureas (glibenclamide 24 [2%], glimepiride 723 [48%], gliclazide 745 [50%]). At baseline, 335 (11%) participants had a previous cardiovascular event. The study was stopped early on the basis of a futility analysis after a median follow-up of 57·3 months. The primary outcome occurred in 105 patients (1·5 per 100 person-years) who were given pioglitazone and 108 (1·5 per 100 person-yea...
Source: The Lancet Diabetes and Endocrinology - September 14, 2017 Category: Endocrinology Source Type: research

Cardioprotective effect of Phyllanthus amarus against high fructose diet induced myocardial and aortic stress in rat model.
The objective of this study is to investigate the cardio-protective activity of aqueous extract of Phyllanthus amarus (PAAE) against high-fructose (HF) diet induced cardiac damage in Wistar rats. Male Wistar rats were randomly assigned into five groups of six animals each: Control (C), Control treated with PAAE (C+PAAE), High fructose diet fed (F), High fructose diet fed treated with PAAE (F+PAAE) and High fructose diet fed treated with Pioglitazone (F+Pio). PAAE was orally administered at a dosage of 200mg/kg body weight/day to C+PAAE and F+PAAE group rats for 60days. Pioglitazone (10mg/kg body weight/day) was used to com...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 19, 2017 Category: Drugs & Pharmacology Authors: Putakala M, Gujjala S, Nukala S, Bongu SBR, Chintakunta N, Desireddy S Tags: Biomed Pharmacother Source Type: research

Cardiovascular effects of pioglitazone or sulphonylureas according to pretreatment risk: moving towards personalized care.
CONCLUSIONS: It is possible to identify patients with type 2 diabetes early in the stage of their disease and largely free from evident cardiovascular disease, in whom add-on pioglitazone to metformin confers cardiovascular protection as compared to sulphonylureas. PMID: 31058962 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Endocrinology and Metabolism - May 5, 2019 Category: Endocrinology Authors: Vaccaro O, Lucisano G, Masulli M, Bonora E, Del Prato S, Rivellese AA, Giorda CB, Mocarelli P, Squatrito S, Maggioni AP, Riccardi G, Nicolucci A, TOSCA.IT investigators Tags: J Clin Endocrinol Metab Source Type: research

Effect of pioglitazone in acute ischemic stroke patients with diabetes mellitus: a nested case –control study
Pioglitazone is an oral antidiabetic drug with multiple pleiotropic actions. Recent clinical trials have demonstrated that treatment with pioglitazone reduces cardiovascular risk in patients who have had an is...
Source: Cardiovascular Diabetology - May 31, 2019 Category: Cardiology Authors: Min-Hee Woo, Hye Sun Lee and Jinkwon Kim Tags: Original investigation Source Type: research

Activation of The Metabolic Master Regulator PPAR γ - A Potential PIOneering Therapy for Pulmonary Arterial Hypertension.
The objective is a data-driven approach to set the preclinical and clinical study record straight. The convincing recent clinical trial data on the lack of significant toxicity in high risk populations justify the timely conduction of clinical studies in order to achieve "repurposing" or "repositioning" of pioglitazone for the treatment of clinical PAH. PMID: 31577451 [PubMed - as supplied by publisher]
Source: Am J Respir Cell Mol... - October 1, 2019 Category: Respiratory Medicine Authors: Hansmann G, Calvier L, Risbano MG, Chan SY Tags: Am J Respir Cell Mol Biol Source Type: research

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
CONCLUSIONS: Pioglitazone reduced or delayed the development of T2DM in people at increased risk of T2DM compared with placebo (low-certainty evidence) and compared with no intervention (moderate-certainty evidence). It is unclear whether the effect of pioglitazone is sustained once discontinued. Pioglitazone compared with metformin neither showed advantage nor disadvantage regarding the development of T2DM in people at increased risk (low-certainty evidence). The data and reporting of all-cause mortality, SAEs, micro- and macrovascular complications were generally sparse. None of the included studies reported on QoL or so...
Source: Cochrane Database of Systematic Reviews - November 19, 2020 Category: General Medicine Authors: Ipsen EØ, Madsen KS, Chi Y, Pedersen-Bjergaard U, Richter B, Metzendorf MI, Hemmingsen B Tags: Cochrane Database Syst Rev Source Type: research